Alnylam Pharmaceuticals, Inc. · Healthcare
Survives a correction-sized 3-point cut to analyst growth.
At a 18.0% margin the price requires 2.9% 3y revenue CAGR against 25.3% consensus, a cushion of +22.1pt versus a 0pt correction cut. Cushion clears the cut, so the price survives the correction on consensus estimates. High-growth biotech, multiple-exposed only; cycle is early in its profit ramp.
Breaks if: Amvuttra ATTR-CM launch misses and the fresh 22.7% consensus margin slips. We re-check this against analyst estimates every evening.
10 years, at a 18% margin analysts expect
+15.9%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
18 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. Two or more red flags: this name cannot come out on top, however large its cushion.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 23, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price at the price sits at the 6th percentile of published models, meaning the market has largely rejected the bull case and is pricing a sharp deceleration from the 65% growth just delivered.
Whether second-line TTR patient volume normalizes into a flat decline or finds a steady, growing baseline — and the available unit volume data can directly measure this.
What the price refuses to pay for, and the full reconstruction, on the ALNY quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names